anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Circulating cell-free mitochondrial DNA (ccf-mtDNA) is an indicator of cell death, inflammation, and oxidative stress. ccf-mtDNA in pregnancies with placental dysfunction differs from that in healthy pregnancies, and the direction of this difference depends on gestational age and method of mtDNA quantification. Reactive oxygen species (ROS) trigger release of mtDNA, yet it is unknown whether trophoblast cells release mtDNA in response to oxidative stress, a common feature of pregnancies with placental pathology. We hypothesized that oxidative stress would induce cell death and release of mtDNA from trophoblast cells. BeWo cells were treated with antimycin A (10-320 µM) or rotenone (0.2-50 µM) to induce oxidative stress. A multiplex real-time quantitative PCR (qPCR) assay was used to quantify mtDNA and nuclear DNA in membrane-bound, non-membrane-bound, and vesicle-bound forms in cell culture supernatants and cell lysates. Treatment with antimycin A increased ROS (P < 0.0001), induced cell necrosis (P = 0.0004) but not apoptosis (P = 0.6471), and was positively associated with release of membrane-bound and non-membrane-bound mtDNA (P < 0.0001). Antimycin A increased mtDNA content in exosome-like extracellular vesicles (vesicle-bound form; P = 0.0019) and reduced autophagy marker expression (LC3A/B, P = 0.0002; p62, P < 0.001). Rotenone treatment did not influence mtDNA release or cell death (P > 0.05). Oxidative stress induces release of mtDNA into the extracellular space and causes nonapoptotic cell death and a reduction in autophagy markers in BeWo cells, an established in vitro model of human trophoblast cells. Intersection between autophagy and necrosis may mediate the release of mtDNA from the placenta in pregnancies exposed to oxidative stress.NEW & NOTEWORTHY This is the first study to test whether trophoblast cells release mitochondrial (mt)DNA in response to oxidative stress and to identify mechanisms of release and biological forms of mtDNA from this cellular type. This research identifies potential cellular mechanisms that can be used in future investigations to establish the source and biomarker potential of circulating mtDNA in preclinical experimental models and humans.
In the event of overdose with JANUMET XR, contact the Poison Control Center.

In the event of an overdose, it is reasonable to employ supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as indicated by the patient's clinical status.

Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session. Prolonged hemodialysis may be considered if clinically appropriate. It is not known if sitagliptin is dialyzable by peritoneal dialysis.

Overdose of metformin has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Warnings and Precautions (5.1)]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.
Codeine: Codeine is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of morphine. The precise mechanism of action of codeine and other opiates is not known; however, codeine is believed to act centrally on the cough center. In excessive doses, codeine will depress respiration. Codeine can produce miosis, euphoria, and physical and physiological dependence.

Chlorpheniramine: Chlorpheniramine is a propylamine derivative antihistamine (H1-receptor antagonist) of the alkylamine class that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa.
A method of preparing sulphoalkyl ether-Î²-cyclodextrin, especially sulphobutyl ether-Î²-cyclodextrin (SBE-Î²-CD), comprises contacting cyclodextrin with a base to form activated cyclodextrin and reacting the activated cyclodextrin with an alkyl sultone, wherein the sulphoalkylation is performed under continuous flow conditions. Typically, the activation is carried out as a batch process and the molar ratio of base to cyclodextrin may be from 2:1 to 22:1. The alkyl sultone may be 1,4-butane sultone and the base may be an alkali metal hydroxide, such as NaOH. Normally, the activation is performed in a first vessel and the alkyl sultone is kept in a second vessel, not directly connected to the first, thereby avoiding the base and sultone reacting together. The molar ratio of sultone to cyclodextrin may be from 7:1 to 33:1. Use of sodium hydroxide to control the degree of substitution of sulphoalkyl ether-Î²-cyclodextrin is also disclosed. A composition and a pharmaceutic excipient containing sulphobutyl ether-Î²-cyclodextrin with a degree of substitution of â¥7.3 is further claimed.
Spontaneous bacterial peritonitis (SBP) is a common and serious complication in cirrhotic patients with a reported mortality rate of 20 to 30%.1-3 A SBP diagnosis requires abdominal paracentesis and is made in the presence of an elevated ascitic fluid absolute polymorphonuclear leukocyte (PMN) count without an evident intra-abdominal, surgically treatable source of infection.2,3 Common pathogens associated with SBP are Gram-negative colonic organisms. However, in recent years, Gram-positive pathogens have become more common, suggesting the need to evaluate SBP management.1,4-6 The recurrence rate of SBP after an initial episode has been reported to be as high as 70%.1-3 Currently, the American Association for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver (EASL) guidelines recommend the use of sulfamethoxazole/trimethoprim, norfloxacin, or ciprofloxacin for the prevention of recurrent SBP. Fluoroquinolones as a class have had increased black box warnings in recent years, making ciprofloxacin fall out of favor for long-term prophylaxis.5 Sulfamethoxazole/trimethoprim is extensively metabolized by the liver and is contraindicated in marked liver impairment.8 Therefore, it is necessary to search for a prophylaxis alternative with similar efficacy and a better safety profile.

Doxycycline is a broad-spectrum antibiotic that covers Gram-positive bacteria, including Streptococcus spp., resistant strains of Staphylococcus and Enterococcus, and Gram-negative bacteria, including Enterobacteriaceae. One randomized trial in cirrhotic patients with a previous episode of SBP showed that doxycycline was associated with a reduction in inflammatory markers, such as interleukin-6 and C-reactive protein, suggesting potential benefits of doxycycline in this patient population.7 At Methodist Dallas Medical Center (MDMC) and the Liver Institute at MDMC, doxycycline has been utilized for both primary and secondary prevention of SBP. In order to compare doxycycline with guideline-directed therapies for SBP prevention in cirrhotic patients, a retrospective, cohort study was designed to review patients who meet the criteria from July 2014 to July 2018. This study aims to compare the efficacy of doxycycline with that of guideline recommended therapies for primary and secondary SBP prophylaxis, the safety of doxycycline with that of guideline recommended therapies for primary and secondary SBP prophylaxis, and identify the association between chemoprophylaxis and the risk of infections from multidrug resistant organisms (MDROs) in SBP.
PURPOSE: To treat a material contg. a phosphocaseinate of divalent cation such as calcium and/or magnesium phosphocaseinate. CONSTITUTION: When a casein-base material contg. a phosphocaseinate of divalent cation is treated, it is hydrolyzed with at least one kind of protease capable of reproducing the digestion of protein caused in a living body and the resultant hydrolyzate is recovered and subjected to at least one ultrafiltration process using a membrane capable of holding phosphopeptide to pass peptide. The resultant filtrate contains phosphoric acid-free peptide contg. >12% arom. amino acids, <4% serine and <10% free amino acids.
PURPOSE:To obtain an antimicrobial and antitumor extract, by pulverizing Aplysis kurodai, extract it with an aqueous solvent, separating and collecting a high-molecular weight fraction of the extract. CONSTITUTION:Aplysia kurodai is pulverized, extracted with an aqueous solvent (e.g., water, various kinds of salts, etc.), the extracted solution is separated preferably by two or more treatments of ultrafiltration, gel filtration, dialysis, ion exchange resin treatment, etc., so that a fraction having >=50,000, preferably 50,000-500,000 is separated and collected. The high-molecular weight fraction has the following properties. Light yellow powder, 7-8pH, and stable to tryptophan. Having improved antibacterial and antitumor activity, and effective against vaious kinds of malignant tumors and microbisms. The titled extract is preferably obtained from Aplysia kurodai by using its roe.
The invention provides a GIT fusion protein used for preventing dairy cow mastitis. The GIT fusion protein has an amino acid sequence as represented by SEQ ID No. 1 or an amino acid sequence which is formed after substitution, deletion or addition of one or a plurality of amino acids of the sequence represented by SEQ ID No. 1 and has same functions as the sequence represented by SEQ ID No. 1 does. The invention also provides the nucleotide sequence of the protein and a preparation method and application for the same. The protein has good immunogenicity, can effectively prevent infection caused by Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus agalactiae and Streptococcus uberis, has a wide immune range and can be used for preventing dairy cow mastitis; moreover, while immunoprotection effects of the GIT fusion protein provided in the invention is guaranteed, preparation process and immune procedures in actual production are simplified, the length of the peptide chain of the fusion protein is shortened, expression of the fusion protein is enhanced, and the GIT fusion protein has an important value in development and application of novel vaccines.
PURPOSE: Early referral of patients with suspicious of rheumatoid arthritis (RA) has an impact on prognosis. Our study aimed to evaluate the clinical characteristics of patients with hands arthralgia who were referred from primary care physicians (PCP) to the rheumatologist.
METHODS: A descriptive, observational, prospective cohort study was performed. We included patients who visited a PCP for the first time for hands arthralgia. Demographics and the European Alliance of Associations for Rheumatology criteria for arthralgia suspicious for progression to RA plus seven complementary questions, the time to referral, the pressure needed to provoke pain with an automatic squeeze test machine in the metacarpophalangeal joints of both hands, and the diagnoses established at the last review of medical charts from patients on follow-up were documented. The primary outcome was the referral to a rheumatologist.
RESULTS: A total of 109 patients were included. The mean age was 49.9 years, 81.6% were women. 30.3% were referred to the rheumatologist. The time to referral was a median of 38 days. The main clinical characteristics associated with referral to the rheumatologist were the "most severe symptoms are present after midnight" (OR=6.29) and the "difficulty with making a fist" (OR=3.67). An isolated "positive squeeze test of metacarpophalangeal joints" was not associated with a referral to the rheumatologist.
CONCLUSIONS: Among patients with hands arthralgia who attended PCP, those with most severe symptoms after midnight and difficulty making a fist were more likely to be referred to the rheumatology clinic. Isolated positive squeeze tests are not a parameter for referral, it should only be performed if arthralgia is clinically suspected.
Cytomegalovirus (CMV) infection and reactivation in solid organ transplant (SOT) recipients increases the risk of viremia, graft failure and death. Clinical studies of CMV serostatus indicate that donor positive recipient negative (D+/R-) patients have greater viremia risk than D-/R-. The majority of patients are R+ having intermediate serologic risk. To characterize the long-term impact of CMV infection and assess viremia risk, we sought to measure the effects of CMV on the recipient immune epigenome. Specifically, we profiled DNA methylation in 156 individuals before lung or kidney transplant. We found that the methylome of CMV positive SOT recipients is hyper-methylated at loci associated with neural development and Polycomb group (PcG) protein binding, and hypo-methylated at regions critical for the maturation of lymphocytes. In addition, we developed a machine learning-based model to predict the recipient CMV serostatus after correcting for cell type composition and ancestry. This CMV episcore measured at baseline in R+ individual stratifies viremia risk accurately in the lung transplant cohort, and along with serostatus the CMV episcore could be a potential biomarker for identifying R+ patients at high viremia risk.
Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein and down-selected epitopes from the Niv F and N proteins (Generation-2 vaccine). Quality controls were performed on vaccine batches. The immunogenicity of both vaccines has been tested in hCD40Tg mice. A dose- dependent IFNg T cell response to the antigen was observed. Three weeks post-boost, specific IgG were detectable in groups immunized with 10ug of vaccine. B cell responses were markedly improved 1 week post-boost. All samples at week -4 showed a neutralization with an average titer at 1:500. The inventors also demonstrated the potency of an innovative DC- targeting vaccine candidate to prevent NiV-B infection in challenge experiments in an AGM model. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Targeting Nipah virus antigens to professional APCs can be efficiently used as a prophylactic means against a Nipah virus challenge at a lethal dose. Accordingly, the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to preparing gelatin mass and capsules made of thereof. Method involves addition of optimal amount of hydrogen peroxide under control of redox-potential value at the range 0.3-0.4 V. The prepared gelatin mass exhibits stable physico-chemical properties (viscosity, elasticity, color, etc.). Capsules made of this mass exhibit bright color, low level of bacterial insemination, stability, etc. Capsules were used for medicinal preparations dosing. EFFECT: improved method of preparing, decreased energy consumption and cost. 1 tbl
The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.
The purpose of this investigation is to field-test a physical function assessment paradigm, designed to inform people of their physical function relative to peers of similar demographic characteristics (e.g., similar age, sex, height, etc.), to promote recommended preventive health behaviors. The physical function assessment paradigm is known as Cafe Move. Our primary research hypothesis is that people will advance along the stages of behavior change (i.e., more likely to participate in recommended preventive healthcare for physical function), after accessing Cafe Move assessments. This study is a single cohort (n=36 participants), double-baseline design, intended primarily to collect pilot data. The results will inform the design of a larger controlled trial.

This study will examine the safety, feasibility, acceptability, and preliminary efficacy of Café Move. Briefly, we will make Café Move available to at-risk populations (i.e., independent-living older adults) via the following approach. First, during a 3-month control phase, we will monitor participants' health behaviors and engagement with preventive health offerings via periodic phone surveys. We will then make Café Move available and subsequently monitor health behaviors and engagement with preventive health offerings. This design will allow us to examine feasibility of the Café Move intervention, to better understand the reach of the program within and across communities, and to determine variance and covariance for the outcome measures of interest.
The present invention relates to a traditional Chinese medicine preparation for treating molluscum contagiosum, which takes more than 10 Chinese herbal medicines of mulberry leaf, common anemarrhena rhizome, raw gypsum, platycodon root etc. as the raw materials. The present invention has the effects of dispelling wind, clearing heat, removing toxicity and removing rash. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation for treating molluscum contagiosum. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
FIELD: medicine. SUBSTANCE: reptiles, belonging to the order Serpents, put into the glass vessel, are exposed to ultraviolet rays. The process is carried out until the reptile bodies are completely dissolved. After that the contents of the vessels is filtered and sterilized at 100 C during one hour. The finished product has pH in the range from 6,8 to 7,2. EFFECT: enhanced effectiveness in treating purulent wounds.
The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
### Absorption

Midazolam is rapidly absorbed after oral administration and is subject to substantial intestinal and hepatic first-pass metabolism. The pharmacokinetics of midazolam and its major metabolite, α-hydroxymidazolam, and the absolute bioavailability of midazolam hydrochloride syrup were studied in pediatric patients of different ages (6 months to <16 years old) over a 0.25 to 1 mg/kg dose range. Pharmacokinetic parameters from this study are presented in Table 1. The mean T values across dose groups (0.25, 0.5, and 1 mg/kg) range from 0.17 to 2.65 hours. Midazolam exhibits linear pharmacokinetics between oral doses of 0.25 to 1 mg/kg (up to a maximum dose of 40 mg) across the age groups ranging from 6 months to <16 years. Linearity was also demonstrated across the doses within the age group of 2 years to <12 years having 18 patients at each of the three doses. The absolute bioavailability of the midazolam hydrochloride syrup in pediatric patients is about 36%, which is not affected by pediatric age or weight. The AUC ratio of α-hydroxymidazolam to midazolam for the oral dose in pediatric patients is higher than for an IV dose (0.38 to 0.75 versus 0.21 to 0.39 across the age group of 6 months to <16 years), and the AUC ratio of α-hydroxymidazolam to midazolam for the oral dose is higher in pediatric patients than in adults (0.38 to 0.75 versus 0.40 to 0.56). max0-∞0-∞

Food effect has not been tested using midazolam hydrochloride syrup. When a 15 mg oral tablet of midazolam was administered with food to adults, the absorption and disposition of midazolam was not affected. Feeding is generally contraindicated prior to sedation of pediatric patients for procedures.
600 elective knee and hip arthroplastic patients are collected. 200 patients before AG- service will be compared to 400 patients after AGS. The latter group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years. Controls will be held after 3 months, 1 year and 5 years after operation including B-Hba1c, 15 D Quality of life assessment and patient interview.

There are several aims of the team and study: to detect, diagnose and optimize treatment (including medication) of diabetic/ dysglycemic patients from preoperative assessment 1 week before operation to postoperative care. With blood glucose target 42 - 86 mmol/mol results better overall survival, lesser complications (i.e. infections, cardiovascular or renal complications) and shorter length of hospital stay. Other aim is to find undiagnosed diabetics or those at risk of developing diabetes. One aim is to find risk factors, which lead to stress hyperglycemia during perioperative period or diabetes in 5 years.
The present invention relates to the fermentation products of cereal and ginseng fruit shells, and the application thereof in a skin cleaning product. According to the method, firstly, a culture medium containing cereal and ginseng fruit shells is heated and sterilized. After that, a microbe is inoculated into the culture medium, and then the culture medium is fermented and sterilized to obtain fermentation products containing a bacterium, a fermentation filtrate and solid particles. The fermentation products are applied to the cleaning product. The cleaning product has the effects of removing grease on the surface of the skin, smoothing the skin, preventing inflammation, removing acnes and the like. Meanwhile, the cleaning product nourishes the skin and gently removes the skin cutin, which is low in irritation, safe and mild.